Status:

WITHDRAWN

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborating Sponsors:

Genzyme, a Sanofi Company

National Cancer Institute (NCI)

Conditions:

Stage IB Melanoma

Stage IIA Melanoma

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating patients wit...

Detailed Description

PRIMARY OBJECTIVES: I. To determine if the alterations in morphology and phenotype to the sentinel lymph nodes are reversible. II. To determine if the restoration of the morphology or phenotype of s...

Eligibility Criteria

Inclusion

  • Patients with stage IB or II cutaneous melanoma
  • Primaries on the torso, upper and lower extremities and head and neck region
  • Skin biopsy performed at least 5 days and no longer than 10 weeks from the time of initial entry into the study
  • Bilirubin \< 2.0 ng/dl
  • Creatinine \< 3.0 ng/dl
  • Able to understand the consent competent to sign
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion

  • Prior wide excision with diameter of the excision \> 3 cm
  • Primary melanoma arises from the eye or mucus membranes
  • Clinical evidence of regional, intransit ,or distant metastases
  • Second invasive melanoma
  • Prior surgical procedures that would alter the drainage patterns and would prevent us from identifying sentinel lymph nodes (SN)
  • Patients with primary or secondary immunodeficiencies
  • Pregnancy
  • Known allergy to sargramostim (GM-CSF)
  • History of cardiac disease, in particular, supraventricular tachycardia

Key Trial Info

Start Date :

August 5 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 8 2017

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01826864

Start Date

August 5 2011

End Date

August 8 2017

Last Update

July 27 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Jonsson Comprehensive Cancer Center

Los Angeles, California, United States, 90095

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma | DecenTrialz